Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Sun J, Shin DY, Eiseman M, Yallowitz AR, Li N, Lalani S, et al. SLITRK5 is a negative regulator of hedgehog signaling in osteoblasts. Nat Commun. 2021;12(1):4611.

Humtsoe JO, Kim H-, Leonard B, Ling S, Keam B, Marchionni L, et al. Newly Identified Members of FGFR1 Splice Variants Engage in Cross-talk with AXL/AKT Axis in Salivary Adenoid Cystic Carcinoma. Cancer Res. 2021;81(4):1001-1013.

Racine-Brzostek SE, Karbaschi M, Gaebler C, Klasse PJ, Yee J, Caskey M, et al. TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. Clin Chem. 2021;67(9):1249-1258.

Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo M-, Avcin T, Bertolaccini ML, et al. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care Res (Hoboken). 2021;73(10):1490-1501.

Plotz B, Castillo R, Melamed J, Magro C, Rosenthal P, H Belmont M. Focal small bowel thrombotic microvascular injury in COVID-19 mediated by the lectin complement pathway masquerading as lupus enteritis. Rheumatology (Oxford). 2021;60(2):e61-e63.

Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12(1):5775.

Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, et al. Author Correction: Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer. 2021;2(11):1243.

Grbesa I, Augello MA, Liu D, McNally DR, Gaffney CD, Huang D, et al. Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity. Cell Rep. 2021;36(10):109625.

Gjyrezi A, Galletti G, Zhang J, Worroll D, Sigouros M, Kim S, et al. Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Commun Biol. 2021;4(1):785.

Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2(4):444-456.